W orldwide, pneumonia is a major cause of childhood morbidity and mortality. A 2015 report found that children younger than 5 years experienced more than 100 million cases each year, and it was the leading cause of death (700 000 deaths each year), particularly in low-income countries. 1, 2 In high-income countries, it is also one of the leading causes of hospitalization in children. 3 Community-acquired pneumonia (CAP) is considered to be most frequently caused by pneumococci, 1, 4 and Streptococcus pneumoniae is a leading cause of death from pneumonia 2 in both adults and children. Before the implementation of pneumococcal conjugate vaccines (PCVs), a few pneumococcal serotypes (mainly serotypes 1, 3, 5, 7F, 14, and 19A) were implicated in proven pneumococcal pneumonia and empyema in children. [5] [6] [7] [8] The implementation of PCV7 led to a transient reduction in the frequency of CAP, 9,10 rapidly followed by an increase in that of CAP with pleural effusion and empyema, 6,11 mainly owing to serotypes 1 and 7F, and an increase in frequency of serotype 19A. 6 When PCV13, which included these additional serotypes, replaced PCV7, the frequency of both CAP and empyema greatly decreased worldwide. 12 Up to 4 years after PCV13 implementation, the frequency of invasive pneumococcal disease was strongly reduced worldwide. 13 However, with a recent increase in its frequency owing to highly invasive non-PCV13 serotypes in England, 14 Germany, 15 and Israel 16, 17 and in pneumococcal meningitis in France, 18 the serotype replacement has raised concerns about the long-term outcome of PCV13 use beyond 5 years after its implementation. However, recent trends observed in invasive pneumococcal disease cannot be extrapolated to CAP. 19, 20 To date, to our knowledge, the association of PCV13 with pneumococcal CAP rates more than 5 years after its implementation remains unknown. We used a time-series analysis of data for children visiting pediatric emergency departments (PEDs) to assess the long-term outcome of PCV13 use on CAP evolution.
Methods
We conducted a quasi-experimental, population-based, interrupted time-series analysis using a multicenter prospective study over 8 years. The data collection was approved by the French National Data Protection Commission. The Robert Debré Hospital ethics committee also approved the study. French legislation does not require any informed consent for this type of study; a mandatory information form validated by the ethics committee was given to all participants.
Study Data and Setting
This prospective, multicenter study was conducted specifically to survey CAP in 8 French PEDs, which were asked to report all cases of CAP from June 2009 to May 2017. The 8 participating hospitals were located in large cities throughout France. We also cross-checked our database with the French hospital system's medicoadministrative database (Programme de Medicalisation des Systems d'Information) to ensure that no case of hospitalized CAP was missed in our data collection.
All pediatric patients in the PEDs who were ages 1 month to 15 years and had chest radiography-confirmed CAP were included. As previously published, 5,21 CAP was defined by the association of fever with chest radiography showing consolidation with or without pleural effusion, diagnosed by a pediatrician and confirmed by a pediatric radiologist. Data collected included clinical characteristics (ie, age, sex, vaccination status, comorbidities), presence of pleural effusion, biological results (including C-reactive protein and/or procalcitonin level, if tested), microbiology samples, hospital admission and/or discharge status, and short-term outcomes.
Microbiology Study
Proven pneumococcal CAP (PP-CAP) was defined by at least 1 of the following 3 conditions: (1) blood or pleural culture positive for S pneumoniae, (2) polymerase chain reactionpositive results for pneumococci on a pleural sample, or (3) pneumococcal antigen test (Binax; Abbott) positivity on a pleural sample. Isolates were serotyped at the National Pneumococcal Reference Center by the capsular swelling method with commercial antisera (Statens Serum Institut). Details of microbiology analyses were previously published.
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Nasopharyngeal wash specimens were obtained for viral testing. The diagnostic process for viral detection was direct immunofluorescence assay and/or polymerase chain reaction for respiratory syncytial virus, influenza A and B, parainfluenza virus, and adenovirus. 22 
Intervention
In June 2010, PCV7 vaccination was replaced by PCV13 vaccination for all infants younger than 2 years, without a catchup program. The current French schedule involves doses at ages 2 months, 4 months, and 12 months, for a total of 3 doses. The coverage with PCV13 was 91.7% among infants aged 9 months in 2011 and remained at levels greater than 91% thereafter. Vaccine coverage was provided by the national public health institute Santé Publique France. 
Key Points
Question In a context of the emergence of nonvaccine serotypes, has the long-term protective outcome of 13-valent pneumococcal conjugate vaccine (PCV13) on community-acquired pneumonia in children eroded?
Findings This time-series analysis of an 8-year prospective multicenter study finds a significant decrease in the frequency of community-acquired pneumonia over 4 years after PCV13 implementation, followed by a slight increase thereafter. The frequency of the most severe cases decreased more markedly, without any rebound.
Meaning Seven years after PVC13 implementation, the protection against pneumonia seems unthreatened by the increase in nonvaccine serotypes recently reported in several countries.
Outcome Measure
The main outcome was the number of CAP cases in children 15 years and younger, per 1000 PED visits. We chose this outcome to take into account the constant increase in total PED visits over time in France. (The evolution of total PED visits in the 8 participating centers is provided in eFigure 1 in the Supplement.) The secondary outcomes were the number of cases of CAP with pleural effusion per 1000 PED visits, the number of cases of CAP with high inflammatory biomarkers (defined as C-reactive protein levels >100 mg/L [to convert to nmol/L, multiply by 9.524] and/or procalcitonin level >4 ng/mL 21 ) per 1000 PED visits, and the number of cases of CAP requiring hospitalization per 1000 PED visits. We also analyzed the number of CAP cases by age group, the number of PP-CAP cases, the serotype distribution, and the rate of virus detection among CAP cases over time.
Control Outcome
Because this study was specifically conducted to analyze CAP, no other pathology was recorded with the same methodology, to provide a control outcome. However, to assess the data quality over time, we analyzed the rate of inflammatory biomarker testing and the rate of virus testing of patients with CAP over time to ensure that changes observed were not because of a change in biologic testing rate.
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Statistical Analysis
The outcomes were analyzed by segmented linear regression with autoregressive error. 24 The time unit chosen was 1 month, to provide optimal precision for the model. 25 Data from the 8 PEDs were aggregated and analyzed together. Because of the overlap between PCV7 and PCV13 implementation during 2010, we defined a 1-year transition period during PCV13 implementation, as previously described.
5,9
We did not define a transition period between the early PCV13 period and late PCV13 period, because neither changes in PCV implementation nor changes in recommendations or regulations occurred. A sensitivity analysis not excluding the transitional period was also performed. All outcomes were adjusted on a national monthly number of influenza-like illness syndromes over time, to take into account influenza epidemics. Data for this adjustment were provided by the French Sentinelle Network.
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The segmented linear regression with an autoregressive error model took into account autocorrelation, seasonality, and trends before and after PCV13 implementation. 24, 25, 27, 28 Seasonality was taken into account using an additive model. The intervention assessment was performed by including 2 dummy variables in the model for each period (early PCV13 and late PCV13), estimating the immediate change after the intervention and the postintervention trend. 25, 27 Thus, the segmented regression model allowed the estimation of each of the immediate changes or trends between periods. In case of CAP number rebound, we determined the knot of CAP increase by using the Akaike information criterion and the maximum likelihood ratio to select the model that provided the best fit.
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All statistical tests were 2-sided, with P < .05 considered statistically significant. The validity of the segmented regression model was assessed by visual inspection of correlograms and residuals analysis. All statistical analyses involved using R version 3.4.3 (R Foundation for Statistical Computing). Table 1) . Before PCV13 implementation, the mean CAP cases per 1000 PED visits estimated by the time-series model was 6.3 cases per month, with a trend of decreasing rates (Figure 1) . The implementation of PCV13 was followed by a persistent and significant decrease in CAP cases during the first 3 years (early PCV13 period, −0.8% [95% CI, −1.0% to −0.5%] per month), with a cumulative 44% decrease (95% CI, −56% to −32%) until May 2014 (from 6.3 to 3.5 cases of CAP per 1000 PED visits). Then, we observed a slight but significant increase per 1000 PED visits during the final 3 years of the study (late PCV13 period, 0.9% [95% CI, 0.4%- 
Results
Population and CAP Number per 1000 PED Visits
Sensitivity Analysis
The segmented regression analysis including the 1-year transition period showed similar results, with a significant Table 2 ).
CAP With Pleural Effusion
The implementation of PCV13 was followed by a marked immediate decrease in cases of CAP with pleural effusion per 1000 PED visits in the early PCV13 period (−48% [95% CI, −84% to −12%]; Figure 2A ). We did not observe any significant trend in the final 3 years (0.7% [95% CI, −0.7% to 2.0%] per month; Figure 2A ; Table 2 ).
CAP Requiring Hospitalization
The implementation of PCV13 was followed by a sharp immediate decrease in cases of CAP requiring hospitalization per 1000 PED visits in the early PCV13 period (−30% [95% CI, −56% to −5%]; Figure 2B ). We did not observe any change in the final 3 years (−0.2% per month [95% CI, −1.2% to 0.7%]; Figure 2B ; Table 2 ).
CAP With High Inflammatory Biomarkers
The implementation of PCV13 was followed by a strong immediate decrease in the number of CAP cases with high inflammatory biomarkers per 1000 PED visits in the early PCV13 period (−30% [95% CI, −54% to −6%]; Figure 2C ). We did not observe any change in the final 3 years (0.5% [95% CI, −0.4% to 1.4%] per month; Figure 2C ; Table 2 ).
Proven Pneumococcal CAP Cases
The implementation of PCV13 was followed by a significant immediate decrease in PP-CAP cases per 1000 PED visits in the early PCV13 period (−54% [95% CI, −97% to −11%]; P = .01; Figure 2D ). We did not observe any change in trend in the final 3 years (0.2% [95% CI, −1.5% to 1.8%] per month; Figure 2D ; Table 2 ). 
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CAP Cases by Age Group
The number of CAP cases followed the same pattern in the 3 age groups (<2.0 years, 2.0 to 4.9 years, and 5.0 to 15.9 years). Figure 3 ; Table 2 ).
Serotype Evolution
In the pre-PCV13 
Control Outcomes
The proportion of virus testing among all CAP cases did not significantly change over the study period (after PCV13 implementation, −0.1% [95% CI, −0.7% to 0.5%] per month; eFigure 4 in the Supplement). Neither did the proportion of inflammatory biomarker testing after PCV13 implementation (0.2% [95% CI, 1.6% to 1.9%] per month; eFigure 4 in the Supplement).
Discussion
This 8-year population-based multicenter prospective study is, to our knowledge, the first to provide data about the long-term association of PCV13 implementation with the frequency of CAP in children more than 5 years after its implementation, with the robust design of a time-series analysis. This study confirmed the association of PCV13 implementation with a decrease in pediatric CAP, with a sharp decline per 1000 PED visits (−44% [95% CI, −56% to −32%]) between June 2010 and May 2014. In the late PCV13 period (June 2014 to May 2017), the number of CAP cases per 1000 PED visits remained far below the pre-PCV13 level, despite a slight but significant increase (0.9% per month; P < .001). In contrast, the late PCV13 period showed no rebound in the frequency of CAP with pleural effusion, CAP requiring hospitalization, CAP with high inflammatory biomarkers, or PP-CAP, which all remained stable at low levels. These results contrast with the recent increase in frequency of invasive pneumococcal disease observed in several countries during the same period 14, 15, 18 linked to serotype replacement beyond 5 years after PCV13 implementation. 14, 15, 18 This difference in the trends suggests different consequences of serotype replacement on pneumococcal CAP vs invasive pneumococcal disease. 19, 20 Moreover, no dominant serotype seems to have emerged, because after PCV13 implementation, none of the 11 non-PCV13 serotypes isolated in CAP were involved in more than 4 cases. The recent slight increase in the number of all CAP cases and virus involvement may reflect changes in the epidemiology of other pathogens and/or serotype replacement with less pathogenic serotypes. These findings should be put in perspective with recent findings from Greenberg et al, 22 who found that during CAP, the most invasive S pneumoniae serotypes, such as 1 and 7F, were carried in nasopharyngeal flora more frequently when no viral coinfection was detected. In contrast, in patients with viral coinfection, carriage rates of the less invasive serotypes (namely, serotypes 33F, 17F, 15 B/C, and 35B) tended to be more frequent. The authors 22 speculated that less invasive serotypes do not typically cause disease unless a virus is present, whereas more invasive pneumonia serotypes may be sufficiently virulent to cause disease without a preceding or concomitant viral infection. The implementation of PCV13 has led to the quasi-disappearance of the more invasive serotypes and increase in others in nasopharyngeal flora, 30 which greatly reduces the frequency of the more severe forms of CAP, but could also play a role in the slight increase in frequency of the more benign forms. A recent systematic review found a global reduction of 31% in CAP cases in children younger than 2 years 12 at 4 years after PCV13 or PCV10 implementation. Six of the 12 studies included in this meta-analysis 12 used the robust design of a time-series analysis, and 5 were based on administrative databases. The most recent data provided were collected in 2014. 12 Several recent studies showed that the early association of PCV13 implementation with rates of pneumonia in children was stronger for CAP with pleural effusion or empyema, 31,32 which agreed with our results. This finding also highlights that the early outcome of PCV13 implementation was stronger with severe pneumonia, which frequently involved the most invasive pneumococcal strains. 1 The strength of the study was to provide data from a multicenter population-based prospective study with the same methodology over 8 years, which allowed for the use of the robust design of time series. 27 This study was specifically conducted to analyze the evolution of CAP over time, thereby avoiding the risks of bias affecting studies based on administrative database recording. 12 The 8 participating PEDs accounted for 9% of all PED annual visits in France. 5 Considering the high number of patients enrolled and the inclusion of both secondary and tertiary PED centers, these data may reflect features of CAP in all French PEDs. Finally, our results appear to be robust and consistent regarding the recent slight increase in global CAP cases in all age groups, the sustaining long-term outcomes of PCV13 implementation on all of the most severe forms of CAP, and the increasing role of viral coinfections.
Limitations
Our study has several limitations. First, the rate of positive blood cultures (4.0%) 21 did not allow for revealing a high proportion of PP-CAP cases. However, a recent large cohort from the United States reported a 2.5% rate of positive blood culture in pediatric CAP, 33 which is consistent with our data. We did not use molecular-based methods for the diagnosis of pneumococcal invasive disease in blood, given their low specificity in children, even if they seem promising. 34 However, our diagnostic process for microbiologic detection did not change over the study period, which enhances the robustness of our findings. Second, given the lack of a control group, we cannot rule out a change in case reporting. However, the analysis of 2 control outcomes reduced the risk of bias owing to any change in biologic testing rate or microbiologic process over time. 35, 36 Moreover, an increased reporting of mild CAP cases and decreased or stable reporting of severe CAP seems unlikely. Furthermore, participating physicians were encouraged to not change their practice, including test use, and no other potential interfering intervention.
Third, the pre-PCV13 period only included the year 2009 to 2010. However, our findings in the early PCV13 period were in line with previous studies assessing the evolution of CAP at 4 years after PCV13 implementation, 12 which attests to the quality and validity of our data and argues for the accuracy of our pre-PCV13 CAP rate.
Conclusions
Despite a slight increase in the overall frequency of CAP cases seen in PEDs since June 2014, 7 years after PCV13 implementation, the association of PCV13 with decreased rates of CAP remains substantial. For the most severe CAP cases (CAP with pleural effusion, CAP requiring hospitalization, and PP-CAP), for which the most invasive pneumococcal serotypes are often implicated, the early substantial decrease was sustained in the later period. The recent reports in several countries of an increase in invasive pneumococcal disease frequency seem not to substantially threaten the long-term benefit of PCV13 implementation on CAP rates. The increasing role of CAP with viral detection suggests an increase in frequency of CAP with viral involvement. 
